Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3,5-dihydroxybenzoic acid (DHBA), also known as alpha-resorcylic acid, is a phenolic acid and a structural isomer of resorcylic acid. In pharmacological research, it is primarily utilized as a selective agonist for the hydroxycarboxylic acid receptor 1 (HCAR1), also known as GPR81 or the lactate receptor. HCAR1 is a G protein-coupled receptor that is highly expressed in adipocytes and various cancer cells, where it typically responds to L-lactate. Research indicates that activation of HCAR1 by DHBA can lead to the up-regulation of the ABCB1 (P-glycoprotein) transporter, a key mediator of multidrug resistance. This mechanism has been specifically linked to increased chemoresistance against agents such as doxorubicin in cervical carcinoma (HeLa) cells, suggesting that HCAR1 signaling plays a significant role in cancer cell survival and drug efflux.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3,5-dihydroxybenzoic acid.